A new kind of specialist is needed at academic medical centers to cope with public health emergencies such as the COVID-19 pandemic: physician-public health practitioners.
A new kind of specialist is needed at academic medical centers to cope with public health emergencies such as the COVID-19 pandemic, argued the authors of an opinion piece in JAMA Health Forum in March.
These “physician-public health practitioners” would be trained in how to build partnerships with community organizations, translate scientific information and provide technical assistance to outsider organizations, wrote Kirsten Bibbins-Domingo, Ph.D., M.D., M.A.S., and Alicia Fernandez, M.D., of the University of California, San Francisco, School of Medicine.
As Bibbins-Domingo and Fernandez note, many academic medical centers have ventured into population health with its focus on prevention and broader issues affecting people’s health status, including upstream, social determinants. In some cases, those population health efforts and programs have led to formal and informal partnerships with community organizations and departments of health.
“These movements in academic medical centers are laudable and, based on our experience, argue for more formal training and recognition of the academic physicians who are leading and partnering with others to advance population health,” they argued.
Bibbins-Domingo and Fernandez point to the 1910 Flexner report as putting U.S. medical school on the path toward research excellence and “enshrinement of the biomedical model of clinical care.” Another Flexner-like overhaul of American medical schools is not in the offing, but they say in light of the 21st century healthcare challenges — they mention obesity, the opioid epidemic and infectious diseases — it is time to invest in another kind of academic clinical leader.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More